PORT HUENEME, CA--(Marketwired - Apr 30, 2015) - Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced the presentation of results from preclinical studies analyzing the immunogenicity of different forms and preparations of Keyhole Limpet Hemocyanin (KLH), and relating to the Company's work in developing methods to identify the appropriate functional properties of KLH for use in immunotherapy and immunodiagnostic applications.

The abstract titled "Measuring the Properties of Different Forms of KLH Reveals Important Differences" will be presented at IMMUNOLOGY 2015 in a poster session at the Annual Meeting of the American Association of Immunologists (AAI) (May 8-12, 2015) at the Ernest Morial Convention Center in New Orleans, Louisiana.

The abstract is authored by Stellar Biotechnologies scientists Shuguang Bi, Ph.D., Laura Milbrandt, and Catherine Brisson, Ph.D. The Company will also exhibit at the AAI meeting (Booth # 648).

KLH is widely used as a carrier protein in immunotherapy vaccine development for diseases such as cancer, immune disorders, inflammatory diseases, and Alzheimer's. KLH is also used extensively in drug immunotoxicology to measure T-cell dependent antibody response.

The poster presentation is a report on Stellar's research in developing functional assays to evaluate the immunogenicity of different forms and preparations of KLH.

"We know that different forms of KLH can elicit different immune responses, so we are developing test methods to identify the suitable form of KLH for any given application," said Dr. Catherine Brisson, Chief Operating Officer at Stellar. "Our goal is to improve the predictive outcome when using KLH as an immunotherapy vaccine carrier or diagnostic immunogen, whether in clinical or research applications."

The poster recaps recent preclinical studies conducted by Stellar comparing the efficiency of various types of KLH to elicit KLH-specific and antigen-specific adaptive immune responses. Dendritic cells (DCs) derived from animal and human cell lines as well as mouse bone marrow mononuclear cells and human peripheral blood mononuclear cells (PBMC) were treated with different forms and preparations of KLH. DC antigen uptake, DC maturation, T-cell proliferation, and cytokine secretion were compared. The studies reveal significantly different responses, the results of which support the need for methods to identify appropriate forms of KLH when used as a hapten carrier or immunogen.

IMMUNOLOGY 2015 Poster Presentation
Title: Measuring the Properties of Different Forms of KLH Reveals Important Differences
Session: Vaccines and Immunotherapy
Date & Time: Saturday, May 9, 2015, 2:30pm - 3:45pm Central (12:30pm - 1:45pm Pacific)
Presenter: Shuguang Bi
Link to poster abstract: https://immunology2015.zerista.com/poster/member/35107
Visit Stellar at AAI Booth # 648.

About Immunology 2015
 Immunology 2015, the Annual Meeting of The American Association of Immunologists (AAI), (www.immunology2015.org) brings together the world leaders in immunology to present their research in lectures and major symposia. The AAI is an association of professionally trained scientists from all over the world dedicated to advancing the knowledge of immunology and its related disciplines, fostering the interchange of ideas and information among investigators, and addressing the potential integration of immunologic principles into clinical practice. AAI owns and publishes The Journal of Immunology.

Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's, and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Visit www.stellarbiotech.com and the Stellar KLH knowledge base www.klhsite.org.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; governmental regulations and the ability or failure to comply with governmental regulations; the timing of anticipated results; and other factors referenced in the Company's filings with securities regulators. For a discussion of further risks and uncertainties related to the Company's business, please refer to the Company's public company reports filed with the TSX Venture Exchange and the U.S. Securities and Exchange Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the information contained in this press release.